TLDR

ARK Invest purchased 781,519 Joby Aviation shares worth $10.4 million on January 29, 2026, following a 16.7% stock decline
Joby Aviation announced a $1 billion capital raise through common stock and convertible notes, triggering investor dilution concerns
ARK sold 31,668 Teradyne shares for $7.9 million as the stock reached $253.61 amid joint venture news with MultiLane
CRISPR Therapeutics received $6.8 million investment from ARK with purchase of 127,184 shares across multiple ETFs
ARK reduced holdings in Veracyte and Illumina while making smaller adjustments to Beam Therapeutics and Kratos Defense positions

Cathie Wood’s ARK Invest executed multiple trades on January 29, 2026, with the largest transaction targeting electric aviation company Joby Aviation. The investment firm disclosed these moves through its daily fund updates.

ARK purchased 781,519 shares of Joby Aviation for a total value of $10.4 million. The shares were acquired through two ETFs: ARK Autonomous Technology & Robotics ETF and ARK Space Exploration & Innovation ETF.

Joby Aviation, Inc., JOBY

The purchase came after Joby Aviation stock fell 16.7% in a single trading session. The decline followed the company’s announcement of a major capital raise. Joby plans to raise approximately $1 billion through a combination of common stock sales and convertible senior notes maturing in 2032.

Market participants expressed concern about potential shareholder dilution from the capital raise. ARK took advantage of the lower price point to increase its position in the air taxi developer.

Gene-Editing Investment Grows

ARK expanded its biotech holdings with a CRISPR Therapeutics stock purchase. The firm acquired 127,184 shares valued at $6.8 million. The transaction occurred across the ARKK and ARKG ETFs.

This purchase represents a continuation of ARK’s buying activity in CRISPR Therapeutics. The firm has been steadily accumulating shares over multiple trading sessions. The gene-editing company’s stock experienced a minor decline during Thursday’s trading.

Semiconductor Position Reduced

ARK Invest divested 31,668 shares of Teradyne for proceeds of $7.9 million. The sale was executed through the ARKQ and ARKX ETFs. Teradyne stock hit an intraday peak of $253.61 during the session.

The sale timing aligned with positive company news. Teradyne and MultiLane announced the formation of a joint venture called MultiLane Test Products. The partnership will address growing demand for high-speed data connection testing in artificial intelligence data centers.

Under the agreement, MultiLane will transfer its test and measurement assets to the new entity. MultiLane retains control of its interconnects and data center test operations. Teradyne will maintain majority ownership of the joint venture.

Additional Portfolio Changes

ARK sold 31,463 Veracyte shares through its ARKK ETF, generating $1.2 million. The firm also decreased its Illumina position by 35,897 shares across ARKK and ARKG. These sales extend ARK’s recent divestment pattern in both companies.

The firm made smaller trades including a 29,413-share purchase of Beam Therapeutics. ARK also sold 261 shares of Kratos Defense and Security Solutions. Wall Street analysts assign a “Moderate Buy” rating to both Teradyne and CRISPR Therapeutics, while Joby Aviation carries a “Hold” rating with projected 41% upside over twelve months.

The post Why Cathie Wood Bought Joby Aviation Stock During Thursday’s 16% Crash appeared first on Blockonomi.

---

Filed under: Bitcoin - @ January 30, 2026 12:29 pm